Danish drugmaker Lundbeck AS has acquired USA-based biotechnology firmSynaptic Pharmaceutical in a deal worth some 851.4 million Danish kroner ($122.5 million). The bid to purchase Synaptic, which specializes in diseases of the central nervous system, was first announced late last year (Marketletter December 2, 2002).
Lundbeck is currently on the acquisition trail and this deal comes after it has already been linked to a move for Bayer AG's pharmaceutical division, as well as that of France's Beaufour Ipsen. The Danish company is targeting growth through external means as it faces up to the threat of increased generic competition for its lead products and rethinks its traditional organic approach to product development. Lundbeck's top-selling drug is the antidepressant Celexa/Cipramil (citalopram), which accounts for 70% of total sales.
Historically, Lundbeck has pursued a highly-focused strategy of specialization with the development of drugs in key indication areas, such as for the treatment of depression. However, with a dearth of home-grown product candidates, the company has acquired Synaptic in a bid to beef up its pipeline. New compounds entering the Lundbeck portfolio include SNEC-2 for the treatment of depression. The drug acts via a completely new mechanism of action and is currently in Phase I clinical trials (Marketletter February 11, 2002).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze